Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
Miao Xue, Yanqin Wu, Bowen Zhu, Xinhua Zou, Wenzhe Fan, Jiaping Li
Abstract
=0.010) than that in the DEB-TACE+SOR group. In conclusion, DEB-TACE+LEN conferred better ORR, OS and TTP than did DEB-TACE+SOR in patients with advanced HCC, especially those with PVTT and FGF21 amplification, with acceptable AEs; thus making it a superior treatment modality for these patients.
Topics & Concepts
MedicineHepatocellular carcinomaHazard ratioSorafenibTranscatheter arterial chemoembolizationLenvatinibInternal medicinePropensity score matchingGastroenterologyRetrospective cohort studyConfidence intervalHepatocellular Carcinoma Treatment and PrognosisFibroblast Growth Factor ResearchCholangiocarcinoma and Gallbladder Cancer Studies